Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 1 de 1
Filter
Add more filters










Database
Language
Publication year range
1.
Biomed Pharmacother ; 89: 1-9, 2017 May.
Article in English | MEDLINE | ID: mdl-28199883

ABSTRACT

Parkinson's disease (PD) is a movement disorder and the second most common neurodegenerative disease worldwide in which nigrostriatal dopaminergic neurons within substantia nigra pars compacta (SNC) are lost, with clinical motor and non-motor symptoms including bradykinesia, resting tremor, rigidity, stooping posture and cognitive deficits. This study was undertaken to evaluate the neuroprotective potential of acetyl-l-carnitine (ALC) against unilateral striatal 6-hydroxydopamine (6-OHDA)-induced model of PD and to explore some involved mechanisms. In this experimental study, intrastriatal 6-OHDA-lesioned rats received ALC at doses of 100 or 200mg/kg/day for 1 week. ALC (200mg/kg) lowered apomorphine-induced rotational asymmetry and reduced the latency to initiate and the total time in the narrow beam test, reduced striatal malondialdehyde (MDA), increased catalase activity and glutathione (GSH) level, prevented reduction of nigral tyrosine hydroxylase (TH)-positive neurons and striatal TH-immunoreactivity, and lowered striatal glial fibrillary acidic protein (GFAP) and its immunoreactivity as an indicator of astrogliosis, and nuclear factor NF-kappa B and Toll-like receptor 4 (TLR4) as reliable markers of neuroinflammation. Meanwhile, ALC at both doses mitigated nigral DNA fragmentation as a valuable marker of apoptosis. The results of this study clearly suggest the neuroprotective effect of ALC in 6-OHDA-induced model of PD through abrogation of neuroinflammation, apoptosis, astrogliosis, and oxidative stress and it may be put forward as an ancillary therapeutic candidate for controlling PD.


Subject(s)
Acetylcarnitine/pharmacology , Corpus Striatum/drug effects , Dopaminergic Neurons/drug effects , Neural Pathways/drug effects , Nootropic Agents/pharmacology , Parkinson Disease, Secondary/prevention & control , Substantia Nigra/drug effects , Animals , Apomorphine/pharmacology , Behavior, Animal/drug effects , Corpus Striatum/metabolism , Dopamine Agonists/pharmacology , Inflammation/chemically induced , Inflammation/prevention & control , Male , Neural Pathways/metabolism , Oxidative Stress/drug effects , Oxidopamine , Parkinson Disease, Secondary/chemically induced , Parkinson Disease, Secondary/psychology , Rats , Rats, Wistar , Substantia Nigra/metabolism , Sympatholytics
SELECTION OF CITATIONS
SEARCH DETAIL
...